| Drug Name |
Selexipag |
| Drug ID |
BADD_D02006 |
| Description |
Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. PAH is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary circulation and decrease elevated pressure in the blood vessels supplying blood to the lungs. |
| Indications and Usage |
Selexipag is indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. |
| Marketing Status |
approved |
| ATC Code |
B01AC27 |
| DrugBank ID |
DB11362
|
| KEGG ID |
D09994
|
| MeSH ID |
C523468
|
| PubChem ID |
9913767
|
| TTD Drug ID |
D0N2SR
|
| NDC Product Code |
66215-718; 66215-602; 66215-612; 47848-060; 70600-007; 66215-606; 66215-616; 66215-610; 66215-614; 70600-029; 66215-628; 66215-604; 66215-608 |
| UNII |
5EXC0E384L
|
| Synonyms |
selexipag | 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide | Uptravi | NS-304 | ACT 293987 | ACT293987 | ACT-293987 |
